Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial

By afschroeder • May 5, 2026

Abdelrahim M, Khan G, Hatoum H, Zervoudakis A, Dayyani F, Zhang L, Li J, Maxwell F, O'Reilly EM, Wainberg ZA, Bullock A. Impact of UGT1A1*28polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. Future Oncol. 2026 May 4:1-8. doi: 10.1080/14796694.2026.2664776. Epub ahead of print. PMID: 42080361.

Tags: Hematology/Oncology, homozygous, Liposomal irinotecan, Metastatic pancreatic ductal adenocarcinoma (mPDAC), NALIRIFOX, NAPOLI 3; SN-38, Publications, UGT1A1*28

Achieving timely treatment for early-stage non-small cell lung cancer: Factors associated with delayed surgical resection and proposed quality benchmarks

Tupper HI, Bhattacharjee J, Sarovar V, Amara D, Schmittdiel JA, Quesenberry CP, Cummings AL, Velotta JB, Sakoda LC. Achieving timely treatment for early-stage non-small cell[...]

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial

Socinski MA, Stahel R, Lee DH, Cappuzzo F, Nishio M, Lovly CM, Ozyilkan O, Li Q, Johnson M, Garon EB, Kilickap S, Ferreira da Silva[...]

The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate Cancer, and Beyond

Chauhan A, Hendifar AE, El-Haddad G, Soares HP, Herrmann K. The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate[...]